|
| Status |
Public on Jun 16, 2021 |
| Title |
S2.1: Sensitive PH039 second passage source tumor (array) |
| Sample type |
genomic |
| |
|
| Source name |
Sensitive PH039 second passage source tumor
|
| Organism |
Homo sapiens |
| Characteristics |
tissue: HGSOC PDX tumor
arm: source tumor arm
|
| Treatment protocol |
HGSOC PH039 PDXs were passed and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment cycles. Following niraparib, mice were monitored by transabdominal ultrasound monitored for regrowth of tumors. RNA sequencing was done on matched baseline tumors and niraparib treated tumors in cycles #1, 2 and 3 in triplicates.
|
| Growth protocol |
HGSOC PH039 PDXs were established intraperitoneally utilizing previously described methods.
|
| Extracted molecule |
genomic DNA |
| Extraction protocol |
Genomic DNA was extracted and purified using Qiagen DNeasy Kit according to standard instructions
|
| Label |
Cy3, Cy5
|
| Label protocol |
DNA was bisulfite converted using the Methylation-Gold kit (Zymo, D5006)
|
| |
|
| Hybridization protocol |
Infinium Methylation EPIC assay ( WG-317-1001)
|
| Scan protocol |
Raw intensity signal from iScan were expoerted to R envirnoment
|
| Description |
Patient-derived xenograft (PDX) high grade serous ovarian cancer model
|
| Data processing |
*.idat files were analyzed using the missmethyl package in R, as outlined in the methods section
annotated beta values normalized using the SWAN method in package missmethyl
|
| |
|
| Submission date |
Jan 18, 2021 |
| Last update date |
Jun 16, 2021 |
| Contact name |
Hu Li |
| E-mail(s) |
li.hu@mayo.edu
|
| Organization name |
Mayo Clinic
|
| Department |
Molecular Pharmacology & Experimental Therapeutics
|
| Lab |
Systems Biology and Pharmacology
|
| Street address |
200 First Street, Gonda Building G19-408
|
| City |
Rochester |
| State/province |
MN |
| ZIP/Postal code |
55904 |
| Country |
USA |
| |
|
| Platform ID |
GPL21145 |
| Series (2) |
| GSE165050 |
Infinium MethylationEPIC BeadChip array data for HGSOC PH039 PDXs at baseline and treated with cycles of 100 mg/kg niraparib for 21 days for four treatment rounds and murine sample. |
| GSE165052 |
Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development |
|
